Grants for For Profit Organizations Other Than Small Businesses

This program provides funding to various organizations and municipalities in New Hampshire for the construction, maintenance, and development of recreational trails for both motorized and non-motorized activities.

This initiative provides cash awards and support to Black-led startups in Brazil, helping them overcome barriers to entrepreneurship and grow their businesses without giving up equity.

In Tier 3, CHEJ's Small Grants Program targets large grassroots organizations with budgets between $250,000 and $1,000,000. Offering grants between $10,000 and $20,000, this tier supports substantial projects that tackle environmental health issues through strategic, impactful actions. Eligible projects are those that enable significant local, state, or regional impact, focusing on building capacity, leadership, and educational outreach within communities affected by environmental toxins. This funding tier is suited for larger organizations that play a pivotal role in their communities and are looking to expand or enhance their ongoing efforts.

The Aquatic Resource Mitigation (ARM) Fund in New Hampshire offers an alternative to permittee-responsible mitigation for unavoidable impacts to aquatic resources such as streams and wetlands through In-Lieu Fee (ILF) payments. These pooled funds are distributed as competitive grants across nine watershed service areas, supporting restoration, enhancement, and preservation activities aimed at compensating for losses and maintaining the state's aquatic resource functions. An annual Request for Proposals is issued by NHDES, the fund's managing entity. Applicants are evaluated by a Site Selection Committee based on criteria including alignment with the state Wildlife Action Plan and expert assessments. The ultimate goal of the ARM Fund is to ensure "no net loss" of aquatic functions and values, emphasizing the creation of sustainable, maintenance-free natural systems within their respective landscapes

This grant provides financial support for Arizona's retail florists to attend out-of-state educational and design events in the floral industry.

Overview: The Google for Startups Ukraine Support Fund aims to provide equity-free cash awards and Google support to assist Ukraine-based startups in sustaining and expanding their businesses, fortifying their community, and establishing a foundation for post-war economic recuperation. Background: Ukraine boasts a robust and dynamic startup ecosystem. However, the nation's economy and its enterprises confront formidable challenges. Startups often operate transnationally, with teams in both Ukraine and neighboring nations, to ensure liquidity, sustain operations, and attract further investment. Google for Startups recognizes the importance of bolstering these endeavors. Funding Details: An initial $5 million fund was allocated in 2022. A subsequent fund of $10 million has been earmarked for 2024 and 2025. Selected startups will be announced on a rolling basis. Each chosen startup will receive up to $100,000 in non-dilutive funding. Ongoing Google mentorship and product support will be provided. Up to $350,000 in Cloud credits will be made available. Purpose: The fund is intended to empower Ukrainian entrepreneurs in sustaining and expanding their ventures amidst the current crisis. It seeks to support startups in maintaining growth trajectories, resuming operations, or pivoting products or operations impacted by the war and ongoing crisis. Entry Criteria: Must have at least one entity registered in Ukraine. Should be at the post-MVP stage with demonstrated traction (product launched, pilots, early revenue). Companies leveraging AI and possessing a social impact mission will receive priority. Founders intending to utilize the non-dilutive cash award for growth continuation, business resumption, or product/operation pivot due to war-induced challenges are encouraged to apply. Deadline June 5th, 2024

With this solicitation, BJS will be seeking an applicant to administer the 2024 National Survey of Victim Service Providers (NSVSP). The NSVSP is part of BJSs Victim Services Statistical Research Program, an effort to develop a statistical infrastructure around victim services and address major gaps in our knowledge about the availability and use of services to support victims of crime or abuse. As a follow-up to the 2023 National Census of Victim Service Providers (NCVSP), the NSVSP will collect more detailed information on services provided, staffing, and organizational constraints from a representative sample of victim service providers (VSPs).

It is the policy of my Administration to advance womens health research, close health disparities, and ensure that the gains we make in research laboratories are translated into real-world clinical benefits for women. It is also the policy of my Administration to ensure that women have access to high-quality, evidence-based health care and to improve health outcomes for women across their lifespans and throughout the country. President Joseph R. Biden, Jr., Executive Order 14120 on Advancing Womens Health Research and Innovation, 18 March 2024.In support of the Presidents Executive Order to advance womens health research, the PRORP is releasing this WHRA funding opportunity. The intent of the FY24 PRORP WHRA is to support research focused on orthopaedic issues faced by women serving in military settings, such as infantry and other physically demanding roles, who have sustained orthopaedic injuries. The overall goal of the WHRA is to address factors that contribute to the health and retention of women in military service. Although use of military populations, datasets, or samples are not required, the application should demonstrate how the proposed research relates to issues faced by women serving in military settings. The proposed research project should also include a well-formulated, testable hypothesis based on sound scientific rationale and logical reasoning.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.The PRORP encourages applications from a spectrum of research areas, including but not limited to translational and clinical research. The PRORP also welcomes qualitative research, population science, and health care services research specifically designed to understand the impact of orthopaedic injuries on female Service Members.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the PRORP WHRAs focus on orthopaedic injuries in women.A key feature of the PRORP WHRA is the relevance to female military and/or Veteran populations following orthopaedic injury. Inclusion of female military and/or Veteran populations is highly encouraged for applications proposing clinical research. Applicants proposing clinical studies in non-military and/or non-Veteran populations must justify the relevance of the proposed research to the military and/or Veteran communities. All applicants should clearly describe how their study design, including recruitment strategies and access to appropriate populations, as applicable, will enable them to meet this intent.Research involving human subjects, human datasets, and human anatomical substances is permitted; however, the WHRA may not be used to conduct clinical trials. Applicants seeking support for a clinical trial should consider the FY24 PRORP Clinical Trial Award (Funding Opportunity Number HT942524PRORPCTA).Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Projects that include research on animal models are required to submit Attachment 7, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE guidelines 2.0 (Animal Research: Reporting In Vivo Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines 2.0 can be found at https://arriveguidelines.org/arrive-guidelines.Encouraged Department of Defense (DOD) and/or VA Collaboration: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the VA, and other federal government agencies are encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP WHRA should not exceed $1.5M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $3.0M to fund approximately two WHRA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

Orthopaedic injuries have a profound impact on military readiness and return to work/activity/duty. In the military, extremity battle wounds comprise approximately 50% of injuries reported in the Department of Defense Trauma Registry. Additionally, orthopaedic injuries and conditions that occur outside of combat (e.g., during training, leisure activities, resultant from old injuries) present one of the greatest threats to the readiness of our Service Members and military. Early stabilization, treatment, and rehabilitation of orthopaedic injuries in both civilian and military populations have led to better outcomes, particularly in the prevention of secondary complications and in minimizing morbidity. Availability of orthopaedic care and treatment as early as possible, or as close to the point of injury as possible, also minimizes limb loss and affects military readiness.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the selected Focus Area.The PRORP CTA supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of military combat or service-related orthopaedic injuries that significantly impact unit readiness and return-to-duty/work rates. Applicants are encouraged to address how the proposed research will support patient care closer to the point of injury and/or allow patients to more quickly return to duty/work. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.The FY24 PRORP CTA differs from the FY24 PRORP Clinical Translational Research Award (CTRA) in that the CTRA allows for clinical research projects that may or may not include a clinical trial, whereas the CTA is restricted to clinical trials only.Funding from this award mechanism must support a clinical trial and may not be used for animal or preclinical studies. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.All applications submitted to this program announcement, regardless of the selected Focus Area, are eligible for Research Level 1.Collaborative Care Option (Research Level 2): Applications submitted to the FY24 PRORP CTA, with Focus Area Translation of Early Findings Soft Tissue Trauma, are eligible for a Collaborative Care Option (Research Level 2); refer to Section II.D.5, Funding Restrictions. The Collaborative Care Option provides additional support to encourage collaborative interdisciplinary research among physical therapists, occupational therapists, prosthetists, surgeons, and other orthopaedic care providers. The proposed research should include both surgical and rehabilitation strategies that create a cohesive project. Surgical strategies are reconstruction and repair and/or application of biologics, pharmaceuticals, and devices for the purpose of restoration of native architecture, composition, and function of traumatically injured tissues. Rehabilitative strategies are those that restore function following injury or illness, with the goal of optimal health and independence. Projects should integrate principles and approaches from surgical and rehabilitative strategies, beyond what each approach would provide by itself, with the goal of optimizing form, function, and independence for those who have sustained traumatic orthopaedic injuries. The rehabilitation strategy and the standard of care must be specified. Projects that follow patients across the continuum of care are highly encouraged. To encourage meaningful and productive multidisciplinary collaborations, projects submitted for this option must include at least one investigator with orthopaedic rehabilitation expertise and at least one clinician who specializes in orthopaedic or trauma care. A Letter of Collaboration is required from each specialist (i.e., rehabilitation expert and surgeon) who is serving as Key Personnel, excluding the Principal Investigator (PI), on the application. A clinician is defined as an individual who is credentialed (possesses the necessary degrees, licenses, and other certifications) and practicing as a care provider in a relevant capacity.If the proposed research includes a clinical trial of an investigational product to be conducted at international sites, an application to the relevant national Regulatory Agency of each host country must be submitted within 6 months of the award date.The government reserves the right to withdraw funding if an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application and/or international regulatory application is necessary but has not been submitted within 6 months of the award date.For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf.Key aspects of the PRORP CTA mechanism: Clinical Trial Start Date: The proposed clinical trial is expected to begin no later than 6 months after the award date, or 12 months after the award date for studies regulated by the Regulatory Agency. Preliminary Data Are Required: Inclusion of preliminary data relevant to the proposed clinical trial is required. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Intervention Availability: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study. Personnel and Environment: The application should demonstrate the study teams expertise and experience in all aspects of conducting clinical trials, including appropriate statistical analysis, knowledge of U.S. Food and Drug Administration (FDA) processes (if applicable), and data management. The application should include a study coordinator(s) who will guide the clinical protocol through the local IRB of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. The application should show strong institutional support and, if applicable, a commitment to serve as the FDA regulatory sponsor, ensuring all sponsor responsibilities described in 21 CFR 312, Subpart D, are fulfilled. Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projections that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If required by a Regulatory Agency, the trial must use a 21 CFR 11-compliant database and appropriate data standards.Womens Health Research: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health.Use of DOD or VA Resources: If the proposed research involves access to DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.For the purposes of this funding opportunity, Regulatory Agency refers to the FDA or any relevant international Regulatory Agency unless otherwise noted.If the proposed clinical trial involves the use of a drug that has not been approved by the relevant Regulatory Agency for the country where the research will be conducted, then submission of an IND application, or equivalent, that meets all requirements under 21 CFR 312 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the relevant Regulatory Agency if an IND, or equivalent, is not required. If an IND, or equivalent, is required, the regulatory application must be submitted to the relevant Regulatory Agency within 6 months of the CTA award start date. The IND, or equivalent, should be specific for the product and indication to be tested in the proposed clinical trial. For more information on IND applications specifically, the FDA has provided guidance at https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application.If the investigational product is a device, then submission of an IDE, or equivalent, application that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence if an IDE, or equivalent, is not required. If an IDE, or equivalent, is required, the IDE application, or equivalent, must be submitted to the relevant Regulatory Agency within 6 months of the CTA award start date. The IDE, or equivalent, should be specific for the device and indication to be tested in the proposed clinical trial.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP CTA should not exceed $2.5M (Research Level 1) or $3.25M (Research Level 2). Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $13.25M to fund approximately four Research Level 1 and one Research Level 2 CTA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

Orthopaedic injuries have a profound impact on military readiness and return to work/activity/duty. In the military, extremity battle wounds comprise approximately 50% of injuries reported in the Department of Defense Trauma Registry. Additionally, orthopaedic injuries and conditions that occur outside of combat (e.g., during training, leisure activities, resultant from old injuries, etc.) present one of the greatest threats to the readiness of our Service Members and military. Early stabilization, treatment, and rehabilitation of orthopaedic injuries in both civilian and military populations have led to better outcomes, particularly in the prevention of secondary complications and in minimizing morbidity. Availability of orthopaedic care and treatment as early as possible, or as close to the point of injury as possible, also minimizes limb loss and affects military readiness.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the selected Focus Area.The FY24 PRORP ARA seeks applied research applications focused on advancing optimal treatment and restoration of function for individuals with orthopaedic injuries sustained during combat and service-related activities. Applicants are encouraged to address how the proposed research will support patient care and allow patients to more quickly return to duty/work. It is expected that any research findings would also provide benefit to the general population. To meet the intent of the award mechanism, applications must specifically address an FY24 PRORP ARA Focus Area, listed in Section II.A.1, above.The FY24 PRORP ARA is focused on applied research, defined as work that refines concepts and ideas into potential solutions with a view toward evaluating technical feasibility of promising new knowledge products, pharmacologic agents, behavioral and rehabilitation interventions, diagnostic and therapeutic techniques, clinical guidance, and/or emerging approaches and technologies.Awards may not be used to support fundamental basic research. Basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind.Research Scope: Research proposed under the FY24 PRORP ARA may include small- to large-scale projects. Upon successful completion, the proposed research is expected to yield knowledge products, approaches, or technologies that have the potential to advance toward clinical translation. Strong transition plans are expected.Inclusion of preliminary and/or published data relevant to the proposed research is required. Applicants must demonstrate logical reasoning for the proposed work. To be competitive, the application must include a sound scientific rationale and a well-formulated, testable hypothesis established through a critical review and analysis of the literature.Studies allowed under the FY24 PRORP ARA may include, but are not limited to: Refinement of concepts and ideas into potential solutions, or research tools, with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new knowledge products. Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic constructs, or devices/systems) in vitro and/or in vivo. Preparation activities needed to support a future clinical trial or regulatory submission.Applications to the FY24 PRORP ARA mechanism must support preclinical applied research and may not be used for clinical research studies. Applicants seeking support for clinical research projects should consider the FY24 PRORP Clinical Translational Research Award (Funding Opportunity Number HT942524PRORPCTRA), Clinical Trial Award (Funding Opportunity Number HT942524PRORPCTA), or Womens Health Research Award (Funding Opportunity Number HT942524PRORPWHRA) mechanisms.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Projects that include research on animal models are required to submit Attachment 8, Animal Research Plan, as part of the application package to describe how these standards will be addressed. Applicants should consult the ARRIVE guidelines 2.0 (Animal Research: Reporting In Vivo Experiments) to ensure relevant aspects of rigorous animal research are adequately planned for and, ultimately, reported. The ARRIVE guidelines 2.0 can be found at https://arriveguidelines.org/arrive-guidelines.Womens Health Research: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health. Applications proposing research that solely address womens health may also consider the FY24 PRORP WHRA mechanism, Funding Opportunity Number HT942524PRORPWHRA.Encouraged Department of Defense (DOD) and/or VA Collaboration: Military relevance is a key feature of this award. Principal Investigators (PIs) are encouraged, but not required, to collaborate with DOD or VA researchers and clinicians.Use of DOD or VA Resources: If the proposed research involves access to DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP Applied Research Award should not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $3.75M to fund approximately five ARA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

Orthopaedic injuries have a profound impact on military readiness and return to work/activity/duty. In the military, extremity battle wounds comprise approximately 50% of injuries reported in the Department of Defense Trauma Registry. Additionally, orthopaedic injuries and conditions that occur outside of combat (e.g., during training, leisure activities, resultant from old injuries) present one of the greatest threats to the readiness of our Service Members and military. Early stabilization, treatment, and rehabilitation of orthopaedic injuries in both civilian and military populations have led to better outcomes, particularly in the prevention of secondary complications and in minimizing morbidity. Availability of orthopaedic care and treatment as early as possible, or as close to the point of injury as possible, also minimizes limb loss and affects military readiness.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the selected Focus Area.The PRORP CTRA is intended to support high-impact and/or emerging clinical research that may not be ready for a full-scale randomized controlled clinical trial. Projects should demonstrate potential to impact the standard of care, both immediate and long-term, as well as contribute to evidence-based guidelines for the evaluation and care of military, Veterans, and all patients with orthopaedic injuries. One goal of the FY24 PRORP CTRA is to translate current and emerging techniques and interventions into the clinical space to better serve military and non-military patients. A holistic approach that takes into account the health, functional abilities, and quality of life of individuals who have sustained an orthopaedic injury should be considered. Another goal is to identify the most effective diagnosis, treatment, rehabilitation, and prevention options available to support critical decision-making for patients, clinicians, other caregivers, and policymakers.The FY24 PRORP CTRA differs from the FY24 PRORP Clinical Trial Award (CTA) in that the CTRA allows for clinical research projects that may or may not include a clinical trial, whereas the CTA is restricted to clinical trials only.Funding from this award mechanism must support clinical research and may not be used for animal research.Clinical research encompasses research with patient samples, data, and interaction with patients that may or may not be considered a clinical trial. Clinical research is observational in nature and includes: (1) Research that does not seek to evaluate the effects of interventions. Research conducted with human subjects (or on material of human origin such as data, tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects but does not seek to assess the effects of an intervention, qualifies as clinical research. Patient-oriented research may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to study the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human tissues that cannot be linked to a living individual. Note: Studies that meet the requirements for exemption under 46.104(d)(4) of the Common Rule are not considered clinical research as defined by the CDMRP. Exemption category 4 refers to secondary research for which consent is not required.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf.Proposed studies submitted to the CTRA may be interventional and may involve some retrospective data analysis. Note that purely retrospective or database-related research is not allowed under this funding opportunity. Small pilot clinical trials with human subjects are allowable.Key aspects of the PRORP CTRA mechanism: Preliminary Data Are Required: Inclusion of preliminary data relevant to the proposed clinical research is required. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical research appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Intervention Availability: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study. Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projections that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If proposing a clinical trial that requires oversight by a Regulatory Agency, the trial must use a 21 CFR 11-compliant database and appropriate data standards.For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted.If the proposed clinical research involves the use of a drug that has not been approved by the relevant Regulatory Agency for the country where the research will be conducted, then submission of an Investigational New Drug (IND) application, or equivalent, that meets all requirements under 21 CFR 312 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the relevant Regulatory Agency if an IND, or equivalent, is not required. If an IND, or equivalent, is required, the regulatory application must be submitted to the relevant Regulatory Agency within 12 months of the CTRA award start date. The IND, or equivalent, should be specific for the product and indication to be tested in the proposed clinical trial. For more information on IND applications specifically, the FDA has provided guidance at https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application.If the investigational product is a device, then submission of an Investigational Device Exemption (IDE), or equivalent, application that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence if an IDE, or equivalent, is not required. If an IDE, or equivalent, is required, the IDE application, or equivalent, must be submitted to the relevant Regulatory Agency within 12 months of the CTRA award start date. The IDE, or equivalent, should be specific for the device and indication to be tested in the proposed clinical trial.Womens Health: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health. Applications proposing research that solely address womens health may also consider the FY24 PRORP WHRA mechanism, Funding Opportunity Number HT942524PRORPWHRA.Use of Department of Defense (DOD) or VA Resources: If the proposed research involves access to DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP CTRA should not exceed $1.5M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $6.0M to fund approximately four CTRA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The U.S. Department of State, Bureau of Democracy, Human Rights, and Labor (DRL) announces an open competition for organizations interested in submitting applications for a project that strengthens the resilience of independent media and advances the protection and inclusion of marginalized populations in Lebanon.

With this solicitation, OJJDP seeks to fund a training and technical assistance (TTA) provider to build capability and capacity of diversion programs serving justice-involved youth populations with substance use disorder and co-occurring mental health and substance use disorder needs. The successful applicant will lead a national TTA program and administer a subaward program providing subawards to local demonstration sites to improve responses and outcomes for youth with substance use disorders and co-occurring mental health and substance use disorders who come into contact with the juvenile justice system, or who are at high risk of contact, by diverting these youth toward community-based treatment to address their unique mental and behavioral health needs to prevent them from entering the formal justice system.

This funding opportunity supports innovative research in microsystems technology, targeting a wide range of applicants including universities, small businesses, and minority institutions, to develop advanced microelectronic systems that enhance U.S. national security.

Key aspects of the MASA: Principal Investigator: The PI (i.e., Scholar) must be an early-career researcher or physician-scientist no more than 7 years from obtaining their first faculty-level appointment. Postdoctoral fellows (and equivalent) are not eligible for this award mechanism. The PIs record of accomplishments and the proposed research will be evaluated regarding their potential for contributing to the FY24 MRP Focus Area(s) in Section II.A.1. Not all of the PIs accomplishments need to be in the field of melanoma. The PIs organization must demonstrate a commitment to the PI through confirmation of independent laboratory space. Impact: The impact of the proposed research must relate to at least one of the FY24 MRP Focus Areas in Section II.A.1. Impactful research, including basic research, should expedite the advancement of promising ideas towards clinical and/or public utility. The application must articulate the short- and long-term impact the proposed research will have on melanoma research and/or patient care. Career Development: A Career Development and Sustainment Plan (Attachment 7) is required and should be prepared with appropriate guidance from the Career Guide. The Career Development and Sustainment Plan should include a clearly articulated strategy for establishing collaborations and acquiring the necessary skills, competencies, and expertise to advance and sustain an independent career at the forefront of the melanoma field. The Scholar must show milestones and career pathways toward achieving the milestones. The Scholar must articulate commitment to interactions with the MA. Career Guide: The Scholar must designate a Career Guide. The Career Guide must be an experienced melanoma researcher, as demonstrated by a strong record of funding and publications in melanoma. In addition, the Career Guide must demonstrate a commitment to advancing the Scholars career in the melanoma field. The Career Guide must also be committed to fully participating in the MA throughout the award period of performance, including interacting with other MA Scholars and Career Guides and participating in MA activities (e.g., serving on the MA Advisory Board) as requested by MA Leadership. The Career Guide must not be the named Career Guide on any previously funded (FY21-FY23) MASA applications, nor may a Career Guide be named on more than ONE FY24 MASA application. Preliminary Data NOT Required: Preliminary data are not required. However, any unpublished, preliminary data presented should originate from the laboratory of the PI or a member of the research team.

The FY24 MRP Idea Award supports innovative, untested, exploratory, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods that address at least one of the FY24 MRP Focus Areas in Section II.A.1. Key aspects of the Idea Award: The intent of the Idea Award is to generate novel research avenues for investigation; therefore, novelty and innovation should be key aspects of the proposed research. Research supported by the Idea Award must introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities. The proposed project must be exploratory, hypothesis-driven, or hypothesis-generating research and be based on a well-developed study design and plan of analysis. Principal Investigators (PIs) new to the melanoma field are encouraged to apply. The Idea Award is NOT intended to expand or extend previously published findings or continue a line of research already established and /or funded in the PIs laboratory. Incremental advances, the next logical step, or merely switching the object or method of inquiry from one cancer to melanoma is not considered innovative. The expected outcome of research supported by this award is the generation of robust preliminary data to be used as a foundation for future melanoma-focused research projects. Inclusion of preliminary data is discouraged. PIs proposing projects already supported by significant preliminary data and/or other funding sources should consider applying to other FY24 MRP funding opportunities for which the inclusion of preliminary data is more appropriate or required. Inclusion of preliminary data other than serendipitous findings is not consistent with the exploratory/innovative nature of this award. If preliminary data are included, they should be unanticipated outcomes or results from an unrelated project or study.

The Boise City Department of Arts & History Catalyst Grant program is a one-time funding opportunity designed to support small-scale and mid-sized arts, history, and cultural activities. These activities include public programs, events, projects, exhibitions, and tours throughout the year. This pilot program aligns with the Department of Arts and History's (A&H) mission to cultivate a distinct sense of place that reflects Boise’s rich past, diverse communities, and unique natural setting. It achieves this by creating opportunities that nurture and sustain Boise’s creative economy, with an overall vision of bringing people together and building positive relationships to create "A City for Everyone." The target beneficiaries of this grant are individuals or representatives of organizations or nonprofit Friends groups associated with a government agency. The projects must directly benefit residents living within Boise City Limits, and if an event is involved, the venue must also be located within Boise City Limits. The impact goals are to strengthen Boise’s cultural base, promote community engagement, and foster a creative economy. The program prioritizes projects that contribute to a distinct sense of place, celebrate Boise's diverse communities, and are accessible to all residents, adhering to Americans with Disabilities Act (ADA) standards and the Department of Arts & History's Equal Opportunity Statement against discrimination. The program focuses on a wide range of arts, history, or cultural initiatives. Examples of activities include public programs like presentations, workshops, walking tours, and trainings; events; performances; exhibits; educational opportunities; oral history projects; collaborations; innovative production that cultivates the cultural community; research, planning, and/or analysis available for Boise residents; and virtual/online projects with a clear intent to reach Boise residents. These diverse activities aim to achieve the broader strategic priorities of the A&H mission. The expected outcomes include the successful execution of numerous small-scale and mid-sized cultural activities that enrich the lives of Boise residents. Measurable results for this one-time pilot program include awarding a standard size of $2,000 per grant, with a total of $40,000 expected to be awarded in FY2024. Five applications are anticipated to be funded in each round. The theory of change for the Boise City Department of Arts & History through this Catalyst Grant is that by providing accessible funding for diverse cultural activities, they will foster a more vibrant and inclusive creative economy, ultimately leading to a stronger sense of community and a more interconnected "City for Everyone."

The Trans Resilience Fund, a grant program of Gender Justice Fund, aims to bolster regional trans communities through a participatory grantmaking process. While the Gender Justice Fund's overarching mission isn't explicitly detailed, the Trans Resilience Fund's focus on supporting trans communities directly aligns with a mission of promoting gender justice and equity. This initiative is a pooled fund, supported by several external funding partners, including the Claneil Foundation, Collective Future Fund, Homeless Assistance Fund, Patricia Kind Family Foundation, and Valentine Foundation for 2024. The collaborative nature of this funding mechanism suggests a strategic priority of collective impact and shared responsibility in addressing the needs of trans individuals. The primary beneficiaries of this grant program are trans communities, with specific prioritization given to groups working in Philadelphia, those serving BIPOC trans communities, groups with trans and/or BIPOC leadership, and organizations serving trans youth, disabled, and/or elderly trans individuals. The impact goal is to provide crucial financial and service-based support to these communities. For instance, smaller organizations exclusively serving trans communities can use funds for direct financial support (food, cash, transportation, medical, housing, utility costs), service provision, organizing, advocacy, and general operating support. This broad range of uses indicates a holistic approach to supporting the well-being and empowerment of trans individuals and groups. The grantmaking committee, comprised of trans and non-binary community members, sets the guidelines and makes funding decisions, embodying a strategic priority of community-led development and self-determination. This participatory approach ensures that funding decisions are informed by the lived experiences and most pressing needs of the target beneficiaries. Organizations with budgets under $250,000, even those not exclusively serving trans communities, can apply for funds for direct financial support, service provision, organizing, and advocacy, while larger organizations (over $250,000 budget) are limited to direct financial support for trans individuals, with 10% of the grant usable for administrative costs. This differentiated approach reflects a strategic awareness of organizational capacity and impact potential across various scales. Expected outcomes include improved health and safety for trans individuals through direct financial assistance, enhanced community support through services, and greater advocacy for trans rights and needs. While specific measurable results are not explicitly outlined, the program's focus on tangible support (e.g., covering medical, housing, or utility costs) and organizational activities (e.g., organizing and advocacy) suggests that success would be measured by the reach and effectiveness of these interventions. The program's theory of change appears to be that by empowering trans and non-binary community members to lead the grantmaking process and by providing flexible funding to a diverse range of organizations, significant positive change can be achieved within trans communities, particularly for those facing compounded vulnerabilities due to race, age, or disability.

This program provides financial assistance to small business and commercial property owners in Jackson, Mississippi, to improve the appearance of their buildings and attract more customers and investors.

Key aspects of the TSA: Multidisciplinary Collaboration: The success of the project should depend on the unique skills and perspectives of each partner. The application must clearly define the synergistic components that will facilitate and accelerate progress in melanoma in a way that could not be accomplished through independent efforts. The plans for interactions among all PIs and institutions involved must be clearly articulated. Collectively, the members of the research team should represent the appropriate diversity of expertise necessary for addressing the proposed research question. Participating institutions must be willing to resolve potential intellectual and material property issues and remove institutional barriers to achieving high levels of cooperation. The following components of the proposed multidisciplinary collaboration are encouraged but not required: It is strongly encouraged that the research team has a least one investigator, key personnel, or consultant who can provide input on the ultimate utility/applicability (short- or long-term) of the anticipated outcome(s) to the melanoma field and/or patient care. The inclusion of an early-career investigator is encouraged. An early-career investigator is defined as an independent, early-career researcher or physician-scientist within 7 years of receiving their first faculty appointment by the time of the full application deadline. Investigators in mentored positions, (e.g., postdoctoral fellows) are not eligible to be named as a PI on a TSA application. The inclusion of a military and/or U.S. Department of Veterans Affairs (VA) investigator is encouraged. A military or VA investigator is defined as an investigator who is active-duty, active reserve, active duty detailed to agencies outside of the Department of Defense (DOD), civilian DOD investigators, or an investigator at a VA research facility. If included as PI on the research team, the military/VA investigator should have a substantial role in the research and should not be included only for access to active-duty military and/or VA populations. Impact: The application must articulate the impact the proposed work, including basic research, will have on melanoma research and/or patient care. Outcomes from this award are expected to expedite the advancement of promising ideas toward clinical applications and/or improve the current state of the science/technology in the melanoma field. The proposed research must relate to at least one of the FY24 MRP Focus Areas in Section II.A.1. Preliminary Data Required: Applications must include preliminary data to support feasibility of the study. However, these data do not necessarily need to be derived from melanoma studies. Any unpublished, preliminary data presented should originate from the laboratory of at least one of the PIs or other member(s) of the research team.